Molbio Diagnostics Raises ₹281.5 Cr from Anchor Investors Ahead of IPO

Molbio Diagnostics Ltd. successfully raised Rs 281.5 crore from anchor investors ahead of its Initial Public Offering. The point-of-care diagnostics company allocated 34.88 lakh equity shares to 33 anchor investors at Rs 807 per share, hitting the upper limit of its IPO price band.

Anchor Investor Breakdown

• Total raised from anchors: Rs 281.5 crore
• Equity shares allocated: 34.88 lakh
• Anchor investors involved: 33
• Price per share: Rs 807
• Domestic mutual funds share: 23.54 lakh shares
• Domestic mutual fund percentage of anchor book: 67.51 percent

Prominent investors included Goldman Sachs, BlackRock Global Funds, Mirae Asset, and Nippon India Mutual Fund. ICICI Prudential Mutual Fund, Kotak Mutual Fund, Tata Mutual Fund, WhiteOak Capital, Bajaj Life Insurance, and HDFC Life Insurance also participated.

Upcoming IPO Details

The IPO is scheduled to open for public subscription from August 10 to August 12. The company aims to raise between Rs 904 crore and Rs 940 crore, with a price band set at Rs 768-807 per share.

• Public subscription dates: August 10 to August 12
• IPO price band: Rs 768-807 per share
• Target IPO raise: Rs 904 crore to Rs 940 crore
• Fresh issue component: Up to Rs 200 crore
• Offer For Sale (OFS) component: Up to 91.66 lakh equity shares

Funds from the fresh issue will primarily cover capital expenditure. This includes Rs 106 crore for an R&D facility, Centre of Excellence, and office space, plus Rs 72 crore for plant and machinery at its Goa and Visakhapatnam units. Remaining funds are for general corporate purposes.

Company Profile & Financials

Molbio Diagnostics, established in 2000, specializes in molecular testing for 30 diseases, including tuberculosis, COVID, and HIV. Its patented ‘Truenat’ platform allows rapid, decentralized diagnosis within an hour, even in resource-limited areas.

• Founded: 2000
• Diseases tested: 30 (e.g., tuberculosis, COVID, HIV, HPV, Hepatitis B and C)
• Manufacturing facilities: 6 across India
• Annual device capacity (March 31, 2026): 5,400 devices
• Annual Truenat test kit capacity (March 31, 2026): 3.9 crore

For fiscal 2026, Molbio reported revenues of Rs 1,445 crore and a profit of Rs 164 crore. The company’s shares are slated for listing on the BSE and NSE on August 17.

Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India, and Motilal Oswal Investment Advisors are serving as the book-running lead managers for the issue.